...
首页> 外文期刊>Diabetes care >Pancreas Transplant Alone: A procedure coming of age.
【24h】

Pancreas Transplant Alone: A procedure coming of age.

机译:单独进行胰腺移植:这是一个成熟的过程。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The goal of this review is to highlight the significant improvements, over the past four decades, in outcomes after a pancreas transplant alone (PTA) in patients with brittle diabetes and recurrent episodes of hypoglycemia and/or hypoglycemic unawareness. A successful PTA-in contrast to intensive insulin regimens and insulin pumps-restores normoglycemia without the risk of hypoglycemia and prevents, halts, or reverses the development or progression of secondary diabetes complications. In this International Pancreas Transplant Registry (IPTR) analysis, we reviewed the records of 1,929 PTA recipients from December 1966 to December 2011. We computed graft survival rates according to the Kaplan-Meier method and used uni- and multivariate analyses. In the most recent era (January 2007-December 2011), patient survival rates were >95% at 1 year posttransplant and >90% at 5 years. Graft survival rates with tacrolimus-based maintenance therapy were 86% at 1 year and 69% at 3 years and with sirolimus, 94 and 84%. Graft survival rates have significantly improved owing to marked decreases in technical and immunologic graft failure rates (P < 0.05). As a result, the need for a subsequent kidney transplant has significantly decreased, over time, to only 6% at 5 years. With patient survival rates of almost 100% and graft survival rates of up to 94% at 1 year, a PTA is now a highly successful long-term option. It should be considered in nonuremic patients with brittle diabetes in order to achieve normoglycemia, to avoid hypoglycemia, and to prevent the development or progression of secondary diabetes complications.
机译:这篇综述的目的是强调在过去的四十年中,在患有脆性糖尿病且反复出现低血糖和/或低血糖意识不足的患者中,单独进行胰腺移植(PTA)后的结果显着改善。与强化胰岛素治疗和胰岛素泵相反,成功的PTA可以恢复正常血糖,而没有低血糖的风险,并且可以预防,中止或逆转继发性糖尿病并发症的发生或发展。在此国际胰腺移植注册管理机构(IPTR)分析中,我们回顾了1966年12月至2011年12月的1,929位PTA接受者的记录。我们根据Kaplan-Meier方法计算了移植物存活率,并使用了单变量和多变量分析。在最近的时代(2007年1月至2011年12月),患者存活率在移植后1年大于95%,在5年大于90%。以他克莫司为基础的维持治疗的移植物存活率在1年时为86%,在3年时为69%,而西罗莫司则分别为94%和84%。由于技术和免疫移植失败率显着降低,移植存活率显着提高(P <0.05)。结果,随着时间的流逝,对后续肾脏移植的需求已显着减少,至5年时仅为6%。患者的一年生存率几乎达到100%,移植物生存率高达94%,因此PTA现在是长期成功的选择。非脆性糖尿病的非尿毒症患者应考虑使用这种药物,以达到正常血糖,避免低血糖并防止继发性糖尿病并发症的发生或发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号